Ibiayi Dagogo‐Jack

Author

Ibiayi Dagogo‐Jack

Massachusetts General Hospital ORCID

Also Known As

I Dagogo‐Jack, I. Dagogo-Jack, IBIAYI DAGOGO-JACK, Ibiayi Dagogo-Jack, Ibiayi Dagogo-jack, Ibiayi Dagogo‐Jack

205

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center Pfizer (United States)

About

Ibiayi Dagogo‐Jack is an author at Massachusetts General Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	2K
2	Health Sciences	6	6	809
3	Cell Biology	5	5	382
4	Engineering	2	2	34
5	Public Health	1	1	34

Ibiayi Dagogo‐Jack

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Cancer Discovery	2016	1.1K
Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i>-Positive Lung Cancer Viola W. Zhu, Satoshi Yoda, Beow Y. Yeap, Journal of Clinical Oncology Lymphoid NeoplasiaAlk-positive NsclcMedicineImmunologyPathology	2018	313
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke, Cancer Discovery	2018	298
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma David Shih, Naema Nayyar, Ivanna V. Bihun, Nature Genetics Tumor HeterogeneityMedicineMetastatic Lung AdenocarcinomaPathologyCancer Genomics	2020	292
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, Diane Tseng, Satoshi Yoda, JCO Precision Oncology	2017	255
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer Stephen V. Liu, Caroline E. McCoach, Viola W. Zhu, Annals of Oncology	2020	216
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors Leila Dardaei, Hui Qin Wang, Manrose Singh, Nature Medicine Alk InhibitorsMedicinePharmacologyBronchial NeoplasmImmune Checkpoint Inhibitor	2018	198
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer Justin F. Gainor, Leila Dardaei, Satoshi Yoda, European Journal of Cancer OncologyAlk-rearranged Lung CancerMolecular MechanismsMedicineBronchial Neoplasm	2016	195
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer Ibiayi Dagogo‐Jack, Satoshi Yoda, Jochen K. Lennerz, Clinical Cancer Research	2020	188
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity Ibiayi Dagogo‐Jack, Marguerite Rooney, Rebecca J. Nagy, Clinical Cancer Research	2019	149

Page 1